Loading
A phase 2 trial of pembrolizumab, lenvatinib and nab-paclitaxel in lung cancer, run by Peking University First Hospital, not yet recruiting.
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients is a phase 2, interventional study registered as NCT06028633 by Peking University First Hospital, with a registry enrolment figure of 28 participants, started 2023-10 and due to reach its primary completion in 2024-10. Interventions recorded: pembrolizumab; lenvatinib; albumin-bound paclitaxel. Conditions listed: Advanced Non-squamous Non-small-cell Lung Cancer; Recurrent Non-Squamous Non-Small Cell Lung Cancer; Metastatic Non-squamous Non Small Cell Lung Cancer. Primary outcome: Objective response rate. Lung eligibility wording from the registry: "Male/female participants who are at least 18 years of age on the day of signing informed consent (ICF) with histologically confirmed diagnosis of metastatic nonsquamous NSCLC (AJCC Staging Manual, Version 8) will be enrolled in this study". Sites: China. No results are recorded here; the registry entry is the source.
Shares Lenvatinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Pembrolizumab and the tag lung-deep-dive.
Shares Nab-paclitaxel, Lung cancer trials open today (registry snapshot), Pembrolizumab, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Nab-paclitaxel, Lung cancer trials open today (registry snapshot), Pembrolizumab, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Nab-paclitaxel, Lung cancer trials open today (registry snapshot), Pembrolizumab, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Nab-paclitaxel, Lung cancer trials open today (registry snapshot), Pembrolizumab, Cytotoxic chemotherapy and the tag lung-deep-dive.